Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosorbents for LDL-apheresis.

S N Pokrovsky1, Adamova IYu, G F Benevolenskaya

  • 1Cardiology Research Center, Institute of Experimental Cardiology, Moscow, USSR.

Biomaterials, Artificial Cells, and Artificial Organs
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The relationship between the level of Lр(а) and the prevalence of atherosclerosis among young patients].

Terapevticheskii arkhiv·2022
Same author

A Sorbent with Synthetic Ligand for Removing Pro-atherogenic and Pro-inflammatory Components from Human Blood Plasma.

Acta naturae·2022
Same author

[Association of lipoprotein (a) with ischemic stroke and stenotic carotid atherosclerosis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2020
Same author

[Lipoprotein(а) Level, Apolipoprotein(а) Polymorphism аnd Autoаntibodies Against Lipoprotein(а) in Patients with Stenotic Cаrotid Atherosclerosis].

Kardiologiia·2019
Same author

[The Relationship of the Concentration of Lipoprotein(a) and Markers of Inflammation with Multifocal Atherosclerosis in Women].

Kardiologiia·2019
Same author

A Low-Molecular-Weight Phenotype of Apolipoprotein(a) as a Factor Provoking Accumulation of Cholesterol by THP-1 Monocyte-Like Cells.

Bulletin of experimental biology and medicine·2019

Researchers developed novel immunosorbents using low-density lipoprotein (LDL) antibodies to selectively remove LDL from human plasma. These "Immunoliposorber" devices are currently in clinical trials for potential therapeutic applications.

Area of Science:

  • Biochemistry
  • Immunology
  • Medical Technology

Background:

  • Low-density lipoprotein (LDL) plays a crucial role in cardiovascular health.
  • Elevated LDL levels are a significant risk factor for atherosclerosis and heart disease.
  • Developing methods for selective LDL removal from plasma is of clinical interest.

Purpose of the Study:

  • To develop and evaluate immunosorbents for the selective removal of LDL from human plasma.
  • To utilize polyclonal (PcAb) and monoclonal (McAb) antibodies against LDL as the basis for these immunosorbents.

Main Methods:

  • Low-density lipoprotein (LDL) was used as an antigen to generate polyclonal and monoclonal antibodies.
  • Antibodies were immobilized to create immunosorbents for selective LDL capture.

Related Experiment Videos

  • The developed immunosorbents are named "Immunoliposorber PcAb" and "Immunoliposorber McAb".

    • Main Results:

    • Successful development of immunosorbents capable of selectively removing LDL from human plasma.
    • The immunosorbents are based on prepared polyclonal and monoclonal antibodies against LDL.
    • The devices are currently undergoing clinical trials.

    Conclusions:

    • The developed "Immunoliposorber PcAb" and "Immunoliposorber McAb" demonstrate potential for selective LDL apheresis.
    • These immunosorbents represent a promising approach for managing hyperlipidemia.
    • Ongoing clinical trials will further validate their efficacy and safety in patient populations.